Multimodal Imaging of ECT Effects

• Status: Active, not recruiting
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The project aims to investigate markers of neural activity and connectivity, neurochemistry, hypothalamic-pituitary-adrenal (HPA) axis activity, inflammation and neuronal plasticity underlying treatment response and remission after ECT. These measures will be assessed in depressive patients prior, during and after ECT and also after 6 months. Furthermore, we will investigate a control group of depressive patients treated with antidepressants.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Charite University, Berlin, Germany
• Treatments: Antidepressive Agents

Criteria

Inclusion Criteria:

• current diagnosis of Major Depression

• severity of current symptoms on a clinical level as indicated by scores of the Hamilton Scale of Depression

• age 25 to 60 in order to exclude cases of late-onset depression and age- associated changes in brain functions and volume

• right handedness

• fluency in spoken and written German

• treatment resistant depression, i.e. at least with two failed antidepressant treatment trials as assessed with the Antidepressant Treatment History Form (ATHF)

Exclusion Criteria:

• history of psychosis or mania, current eating disorder, obsessive- compulsive disorder (OCD), current self-harm, current substance abuse or dependence

• history of traumatic brain injury

• current treatment with glutamate- modulating medication.